Lisa Schwartz

Q: What Schools Are Affiliated With Lisa Schwartz

Lisa Schwartz is affiliated with the following schools: Harvard University, Binghamton University, Dartmouth College, Johns Hopkins University, University of California, San Francisco, Massachusetts General Hospital

Lisa Schwartz 's AcademicInfluence.com Rankings

Lisa Schwartz

Philosophy

#10236

World Rank

#14008

Historical Rank

#1874

USA Rank

Logic

#7141

World Rank

#8800

Historical Rank

#1038

USA Rank

philosophy Degrees

Download Badge

Philosophy

Lisa Schwartz 's Degrees

Doctorate Medicine Harvard University

Why Is Lisa Schwartz Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Lisa M. Schwartz was a Professor of Medicine and Community and Family Medicine at The Dartmouth Institute for Health Policy and Clinical Practice. She was the co-Director of the Center for Medicine and the Media, and ran courses for health journalists on how to report medical research. She created the Drug Facts Box to discuss the benefits and harms of prescription drugs and the National Cancer Institute Know Your Chances site to communicate cancer risks.

(See a Problem?)

Lisa Schwartz 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Helping Doctors and Patients Make Sense of Health Statistics (2007) (1063)
The Role of Numeracy in Understanding the Benefit of Screening Mammography (1997) (1058)
Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. (2010) (613)
Enthusiasm for cancer screening in the United States (2004) (514)
Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000 (2004) (393)
Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? (2003) (354)
Population-Based Risk for Complications After Transthoracic Needle Lung Biopsy of a Pulmonary Nodule: An Analysis of Discharge Records (2011) (350)
A genetic risk factor for periodic limb movements in sleep. (2008) (349)
Do Physicians Understand Cancer Screening Statistics? A National Survey of Primary Care Physicians in the United States (2012) (263)
Distribution of C-reactive protein values in the United States. (2005) (260)
When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found (2013) (243)
Using a Drug Facts Box to Communicate Drug Benefits and Harms Two Randomized Trials (2009) (237)
Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review (2010) (235)
Skin biopsy rates and incidence of melanoma: population based ecological study (2005) (233)
Direct-to-consumer advertisements for prescription drugs: what are Americans being sold? (2001) (211)
Is language a barrier to the use of preventive services? (1997) (195)
Medical Marketing in the United States, 1997-2016 (2019) (194)
Press releases: translating research into news. (2002) (184)
Assessing Values for Health: Numeracy Matters (2001) (182)
Cancer survival: an overview of measures, uses, and interpretation. (2014) (168)
Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. (2005) (164)
Overdiagnosis: what it is and what it isn’t (2018) (161)
How do elderly patients decide where to go for major surgery? Telephone interview survey (2005) (148)
A New Scale for Assessing Perceptions of Chance (2000) (146)
Too Little? Too Much? Primary care physicians' views on US health care: a brief report. (2011) (142)
Risk communication in clinical practice: putting cancer in context. (1999) (134)
Influence of medical journal press releases on the quality of associated newspaper coverage: retrospective cohort study (2012) (124)
Can Patients Interpret Health Information? An Assessment of the Medical Data Interpretation Test (2005) (123)
What do you mean, a spot?: A qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules. (2013) (123)
Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks (2006) (121)
The Media Matter: A Call for Straightforward Medical Reporting (2004) (118)
Women's Perceptions of Breast Cancer Risk (1999) (115)
Giving Legs to Restless Legs: A Case Study of How the Media Helps Make People Sick (2006) (112)
When do changes in cancer survival mean progress? The insight from population incidence and mortality. (2014) (112)
The risk of death by age, sex, and smoking status in the United States: putting health risks in context. (2008) (112)
The Drug Facts Box: Providing Consumers with Simple Tabular Data on Drug Benefit and Harm (2007) (109)
Press Releases by Academic Medical Centers: Not So Academic? (2009) (107)
Resource use and guideline concordance in evaluation of pulmonary nodules for cancer: too much and too little care. (2014) (105)
Cancer screening campaigns--getting past uninformative persuasion. (2012) (96)
Perceived adequacy of tangible social support and health outcomes in patients with coronary artery disease (1997) (87)
News media coverage of screening mammography for women in their 40s and tamoxifen for primary prevention of breast cancer. (2002) (87)
Media coverage of scientific meetings: too much, too soon? (2002) (86)
The Drug Facts Box: Improving the communication of prescription drug information (2013) (86)
Celebrity endorsements of cancer screening. (2005) (80)
Screening for cervical cancer: will women accept less? (2005) (75)
Advertising by academic medical centers. (2005) (74)
Providing clinicians and patients with actual prognosis: cancer in the context of competing causes of death. (2014) (73)
Winding back the harms of too much medicine (2013) (68)
Risk charts: putting cancer in context. (2002) (68)
The benefits and harms of mammography screening: understanding the trade-offs. (2010) (68)
Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. (2007) (68)
Media reporting on research presented at scientific meetings: more caution needed (2006) (67)
Communicating Data About the Benefits and Harms of Treatment (2011) (66)
Communicating uncertainties about prescription drugs to the public: a national randomized trial. (2011) (65)
‘The thing is not knowing’: patients' perspectives on surveillance of an indeterminate pulmonary nodule (2015) (58)
Overdiagnosis: How cancer screening can turn indolent pathology into illness (2014) (56)
Low "T" as in "template": how to sell disease. (2013) (54)
Ramifications of screening for breast cancer: 1 in 4 cancers detected by mammography are pseudocancers (2006) (53)
When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations (2008) (53)
The Effectiveness of a Primer to Help People Understand Risk (2007) (53)
The value of benefit data in direct-to-consumer drug ads. (2004) (52)
Choosing where to have major surgery: who makes the decision? (2007) (50)
The sea of uncertainty surrounding ductal carcinoma in situ--the price of screening mammography. (2008) (49)
Patients and medical statistics. Interest, confidence, and ability. (2005) (48)
How a charity oversells mammography (2012) (47)
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis (2018) (47)
Patients’ Knowledge, Beliefs, and Distress Associated with Detection and Evaluation of Incidental Pulmonary Nodules for Cancer: Results from a Multicenter Survey (2016) (46)
Setting the revisit interval in primary care (1999) (46)
Lost in transmission--FDA drug information that never reaches clinicians. (2009) (45)
Physicians' Knowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation. (2016) (43)
The Fate of FDA Postapproval Studies. (2017) (43)
ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials (2016) (37)
The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? (2014) (36)
Overdiagnosed: Making People Sick in the Pursuit of Health (2011) (36)
Late outcomes after laparoscopic surgery for gastroesophageal reflux. (2002) (36)
A Randomized Trial Testing US Food and Drug Administration "Breakthrough" Language. (2015) (35)
Patients and medical statistics (2005) (35)
Symptoms and treatment burden of gastroesophageal reflux disease: validating the GERD assessment scales. (2004) (34)
Population-based risk of complications following transthoracic needle lung biopsy of a pulmonary nodule (2011) (33)
Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications (2015) (32)
Flawed inferences about screening mammography's benefit based on observational data. (2009) (32)
The role of patients and providers in the timing of follow-up visits (1999) (30)
Numbers needed to decide. (2009) (30)
Promoting healthy skepticism in the news: helping journalists get it right. (2009) (29)
How the FDA forgot the evidence: the case of donepezil 23 mg (2012) (28)
Who’s watching the watchdogs? (2008) (27)
What's the rush? The dissemination and adoption of preliminary research results. (2006) (25)
Focusing on overdiagnosis as a driver of too much medicine (2018) (23)
US Food and Drug Administration Approval of Flibanserin: Even the Score Does Not Add Up. (2016) (23)
What's Making Us Sick Is an Epidemic of Diagnoses (2007) (23)
Implications of expanding disease definitions: the case of osteoporosis. (2007) (22)
Using radiology reports to encourage evidence-based practice in the evaluation of small, incidentally detected pulmonary nodules. A preliminary study. (2014) (21)
Participation in mammography screening (2007) (21)
Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis (2017) (20)
Establishing a library of resources to help people understand key concepts in assessing treatment claims—The “Critical thinking and Appraisal Resource Library” (CARL) (2017) (20)
How Do Women View Risk-Based Mammography Screening? A Qualitative Study (2018) (19)
Making sense of risk information on the web (2003) (18)
A Clear-eyed View of Restasis and Chronic Dry Eye Disease. (2018) (18)
Know Your Chances: Understanding Health Statistics (2008) (17)
Clinical Equipoise and Shared Decision‐making in Pulmonary Nodule Management. A Survey of American Thoracic Society Clinicians (2017) (17)
Older Patients Perceptions of “Unnecessary” Tests and Referrals (2008) (17)
Physicians' Perspectives on FDA Approval Standards and Off-Label Drug Marketing. (2019) (16)
Characteristics of Interim Publications of Randomized Clinical Trials and Comparison With Final Publications (2018) (15)
Direct-to-consumer advertisements for HIV antiretroviral medications: a progress report. (2007) (14)
Attitudes about low-dose computed tomography screening for lung cancer: a survey of American Thoracic Society Clinicians. (2015) (14)
Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis (2018) (14)
Trends in Testosterone Prescribing for Age-related Hypogonadism in Men With and Without Heart Disease (2019) (13)
Know Your Chances (2008) (13)
Marketing medicine to the public: a reader's guide. (2002) (12)
Overcoming overuse: the way forward is not standing still—an essay by Steven Woloshin and Lisa M Schwartz (2018) (11)
Psychotropic medications for highly vulnerable children (2018) (11)
Group writing of letters to the editor as the goal of journal club. (2006) (10)
Bringing the FDA's Information to Market. (2009) (10)
Tobacco money: up in smoke? (2002) (10)
On the prevention and treatment of exaggeration (2003) (9)
The exaggerated relations between diet, body weight and mortality: the case for a categorical data approach (2005) (9)
Knowing your chances (2009) (8)
Quantitative Literacy Assessments: An Introduction to Testing Tests (2009) (8)
Translating Research Into News (2002) (8)
Medical communication companies and continuing medical education: clouding the sunshine? (2013) (8)
Cancer Center Advertising-Where Hope Meets Hype. (2016) (7)
US Food and Drug Administration and design of drug approval studies. (2014) (7)
Overstating the Evidence for Lung Cancer Screening (2007) (7)
Language Barriers in Medicine-Reply (1995) (7)
Accountable prescribing. (2013) (7)
Smoke-free movies: sense or censorship? (2002) (6)
Internal Medicine Physicians’ Financial Relationships with Industry: An Updated National Estimate (2018) (6)
Estimating the Impact of Adding C-Reactive Protein as a Criterion for Lipid Lowering Treatment in the United States (2007) (6)
A National Survey of the Frequency of Drug Company Detailing Visits and Free Sample Closets in Practices Delivering Primary Care. (2020) (6)
Reducing the risk that patients get it wrong. (2005) (5)
Visual Representations of Risk Enhance Long-Term Retention of Risk Information: A Randomized Trial (2019) (5)
Tobacco Use and Respiratory Symptoms Among Adults: Findings From the Longitudinal Population Assessment of Tobacco and Health (PATH) Study 2014–2016 (2022) (4)
Not so silver lining. (2011) (4)
Validation of an Index for Functionally Important Respiratory Symptoms among Adults in the Nationally Representative Population Assessment of Tobacco and Health Study, 2014–2016 (2021) (3)
Tobacco money: up in smoke? (2002) (3)
Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug Promotion. (2019) (3)
Association of aspirin use and hormone receptor status with breast cancer risk. (2004) (3)
Who’s Behind the Numbers? (2008) (2)
FDA and the Media: Lessons from Tysabri about Communicating Uncertainty (2015) (2)
Getting to Better Prescription Drug Information (2012) (2)
Promotion of "low T" and the role of testosterone clinical trials--reply. (2014) (2)
Media Coverage of Scientific Meetings (2017) (2)
QUALITY OF TRIALS Impact of a Systematic Review on Subsequent Clinical Research : The Case of the Prevention of Propofol Injection Pain (2013) (2)
Tobacco money: up in smoke? Authors' reply (2002) (2)
Choosing Where to Have Major Surgery (2015) (2)
The Finding (2012) (2)
absolute risks structured review of accessibility of underlying Ratio measures in leading medical journals (2007) (1)
Computer-Based Decision Support : Wishing on a Star ? (1)
Fractional flow reserve-guided PCI in stable coronary disease. (2012) (1)
COMMENTARY Risk Charts: Putting Cancer in Context (2002) (1)
Patient Responses To The Diagnosis Of A Pulmonary Nodule: Insight From Focus Groups (2011) (1)
Ramifications of screening for breast cancer (2006) (1)
Caution on Interpreting the Time Trends in Pulmonary Embolism as “Overdiagnosis”—Reply (2011) (1)
The Public's Enthusiasm for Cancer Screening [3] (multiple letters) (2004) (1)
Tobacco product use and functionally-important respiratory symptoms among US adolescents/young adults. (2022) (1)
Erratum to: Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications (2015) (1)
What This Book is About (2008) (1)
Drug treatment of obesity--reply. (2014) (0)
Practice Guidelines: The Authors Respond (2008) (0)
RESPONSE: Re: Risk Charts: Putting Cancer in Context (2002) (0)
Consider the Downsides (2008) (0)
The Fate of FDA Postapproval Studies. (2017) (0)
M1135 When Should Ulcerative Colitis Patients Undergo Colectomy for Dysplasia? Mismatch Between Patient Preferences and Physician Recommendations (2008) (0)
9. Seeing through the hype: Garbage! When the news is not fit to print (2013) (0)
[Table, Understanding Risk]. (2008) (0)
[Table], The numbers in the chart tell you how many out of 1,000 fifty-year-old women will die in the next 10 years from . . . (2008) (0)
Credible Sources of Health Statistics (2008) (0)
The Fate of FDA Postapproval Studies. (2017) (0)
Response: Re: Promoting Healthy Skepticism in the News: Helping Journalists Get It Right (2010) (0)
[Table, About This Book]. (2008) (0)
Know Your Chances: Understanding Health Statistics Book Discussion Final Report (2016) (0)
Medicine and the Media: Good Information or Misleading Hype? (2007) (0)
Cancer Care Institutions and Advertising-Reply. (2016) (0)
Can I Reduce My Risk (2008) (0)
Does Direct-to-Consumer Prescription Drug Advertising Do More Harm Than Good? (2009) (0)
8. Seeing through the hype: problems with media coverage and how to do better (2013) (0)
Understanding the Trade-offs The Benefits and Harms of Mammography Screening: (2010) (0)
Number Converter and Risk Charts (2008) (0)
[Box], Learn More (2008) (0)
Emotional Distress Associated With Incidental Pulmonary Nodules: Results From A Multi-Center Patient Survey (2012) (0)
Beware of Exaggerated Certainty (2008) (0)
Putting Risk in Perspective (2008) (0)
Authors’ reply to Quantrill, Benger, Ripley and colleagues, Roach, Rogers, and Haldar and colleagues (2013) (0)
[Table], Number Converter (2008) (0)
The Public's Enthusiasm for Cancer Screening—Reply (2004) (0)
LANGUAGE BARRIERS IN MEDICINE. AUTHORS' REPLY (1995) (0)
Do the Benefits Outweigh the Downsides (2008) (0)
Training in Uncertainty Has Value for Primary Care Physicians: Overreliance on Technology Can Be Remedied—Reply (2012) (0)
Beware of Exaggerated Importance (2008) (0)
FDA Regulation Off-Label Promotion and the First AmendmentBy (2011) (0)
STAT-Interest and -Confidence Scales (2019) (0)
What Is My Risk (2008) (0)
Developing a Healthy Skepticism (2008) (0)
Conservative Prescribing and the Importance of Psychotherapy—Reply (2012) (0)
A, The chance of dying in the next 10 years (2008) (0)
Not All Benefits Are Equal (2008) (0)
Medical Data Interpretation Test (2016) (0)
B, The chance of not dying in the next 10 years (2008) (0)
Disclosure of study funding and author conflicts of interest in press releases and the news: a retrospective content analysis with two cohorts (2021) (0)
Does Risk Reduction Have Downsides (2008) (0)
[Table], The numbers in the chart tell you how many out of 1,000 women of various ages will die in the next 10 years from colon cancer. (2008) (0)
Appropriate Perspective and Context for Newly Approved Medications, Including Flibanserin-Reply. (2016) (0)
Communicating Benefits and Harms of Treatment (2011) (0)
Chapter 21 – Complementary and Alternative Medicine in the Older Cancer Patient (2012) (0)
Judging the Benefit of a Health Intervention (2008) (0)
[Table], Find the line with a specific age and smoking status. The numbers in that row tell you how many out of 1,000 women in that group will die in the next 10 years from . . . (2008) (0)
General Numeracy Test (2020) (0)

This paper list is powered by the following services:

Other Resources About Lisa Schwartz

en.wikipedia.org

What Schools Are Affiliated With Lisa Schwartz ?

Lisa Schwartz is affiliated with the following schools:

Lisa Schwartz 's Academic­Influence.com Rankings